HCWB vs. EQ, IMMX, KZR, MURA, EGRX, LTRN, CELU, SCYX, KRON, and MNOV
Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Equillium (EQ), Immix Biopharma (IMMX), Kezar Life Sciences (KZR), Mural Oncology (MURA), Eagle Pharmaceuticals (EGRX), Lantern Pharma (LTRN), Celularity (CELU), SCYNEXIS (SCYX), Kronos Bio (KRON), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry.
Equillium (NASDAQ:EQ) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.
Equillium has a net margin of -36.96% compared to Equillium's net margin of -879.49%. HCW Biologics' return on equity of -51.82% beat Equillium's return on equity.
Equillium has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
27.1% of Equillium shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 30.3% of Equillium shares are held by insiders. Comparatively, 45.3% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Equillium presently has a consensus price target of $3.90, indicating a potential upside of 126.74%. Given HCW Biologics' higher probable upside, equities research analysts plainly believe Equillium is more favorable than HCW Biologics.
Equillium has higher revenue and earnings than HCW Biologics. Equillium is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Equillium received 27 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 82.50% of users gave Equillium an outperform vote.
In the previous week, HCW Biologics had 1 more articles in the media than Equillium. MarketBeat recorded 1 mentions for HCW Biologics and 0 mentions for Equillium. HCW Biologics' average media sentiment score of 0.00 equaled Equillium'saverage media sentiment score.
Summary
Equillium beats HCW Biologics on 11 of the 16 factors compared between the two stocks.
Get HCW Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCW Biologics Competitors List
Related Companies and Tools
